崔永萍 研究员，博士生导师

Email：cuiyp@sphmc.org

崔永萍，深圳北京大学香港科技大学医学中心肿瘤研究所所长，深圳湾实验室肿瘤研究所詹启敏课题组co-PI，研究员，博士生导师。享受国务院政府特殊津贴专家，入选国家“万人计划”领军人才、国家百千万人才工程国家级人选、国家有突出贡献中青年专家、深圳市国家级领军人才、全国巾帼建功标兵等。

崔永萍团队长期聚焦中国食管鳞癌致病机制研究，取得多项突破性成果。团队建立了全球最大的食管鳞癌单病种多模态组学数据平台，首次提出中国人群食管鳞癌精确分型体系及相应精准治疗策略，创新开发了基于病理图像的AI智能辅助诊疗工具，为分型体系的临床可及性与转化应用潜力提供了技术支撑，为建立食管癌诊疗“中国方案”作出重要贡献。近年来在肿瘤领域相关的主流学术（SCI收录）杂志Cancer Cell、Cell Research、Signal Transduct Target Ther、Nature communications、National Science Review等共发表SCI论著40余篇，论文被SCI他引1700余次，多次被Science、Nature 期刊文章所引用。获批国家级项目近 20 项，包括国家重点研发计划“常见多发病防治研究”重点专项、国家自然科学基金重点项目、国家自然科学基金专项项目、科技部“重大慢性非传染性疾病防控研究”重点专项等，荣获中国抗癌协会科技二等奖、山西省自然科学一等奖等。

代表性论文：

1. Heyang Cui#, Zhongxu Zhu#, Enwei Xu#, Lin Qi#, Yikun Cheng#, Yinghan Zhang#, Ling Zhang, Matthew Yibo Cheng, Bin Yang, Ruifang Sun, Xiaofei Zhuang, Yanfeng Xi, Ting Yan, Caixia Cheng, Ning Ding, Huijuan Liu, Lu Wang, Min Guo, Dinghe Guo, Haoyu Zhang, Meilan Peng, Zhekun An, Yongjia Weng, Fang Wang, Meng Liu, Ruixin Xiong, Bin Song, Weihua Yin, Weimin Zhang*, Xiaolong Cheng, Zhihua Liu, Qimin Zhan*, Xin Wang*, Yongping Cui*. The consensus molecular subtypes of esophageal squamous cell carcinoma. Signal Transduct Target Ther. 2026 Feb 19;11(1):65. (IF = 52.7)

2. Qiqin Song, Mingwei Gao, Yongjia Weng, Xuehan Zhuang, Yueguang Wu, Heyang Cui, Ning Ding, Longlong Wang, Shanshan Bi, Li Zhang, Weimin Zhang*, Yongping Cui*. Evolutionary adaptation and asymmetric inheritance of polyploid giant cancer cells in esophageal squamous cell carcinoma. Cancer Letters. 2025 May 23:217818. doi: 10.1016/j.canlet.2025.217818. (IF=10.1)

3. Yueguang Wu#, Heyang Cui# , Longlong Wang, Ning Ding, Yongjia Weng, Yikun Cheng, Shanshan Bi, Heng Xiao, Mingwei Gao, Huijuan Liu, Qiqin Song, Weimin Zhang*, Yongping Cui*. IRF2BPL transcriptionally regulates IGFBP2 to promote tumor progression and suppresses immune cell infiltration in esophageal squamous cell carcinoma. Oncogene. 2025. Dec.18. (IF=7.3)

4. Yong Zhou#, Shanlan Mo#, Heyang Cui#, Ruifang Sun#, Weimin Zhang#, Xiaofei Zhuang#, Enwei Xu, Hongyi Li, Yikun Cheng, Yongsheng Meng, Meilin Liu, Ting Yan, Huijuan Liu, Ling Zhang, Bin Yang, Yanfeng Xi, Shubin Wang, Xiaolong Cheng, ShuaiCheng Li, Zhihua Liu*, Qimin Zhan*, Zheng Hu*, Yongping Cui*. Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma. National Science Review. 2024; nwae150. (IF=17.1)

5. Zhihua Liu*, Yahui Zhao, Pengzhou Kong, Yuhao Liu, Jing Huang, Enwei Xu, Wenqing Wei, Guangyu Li, Xiaolong Cheng, Liyan Xue, Yi Li, Hongyan Chen, Shuqing Wei, Ruifang Sun, Heyang Cui, Yongsheng Meng, Meilin Liu, Yang Li, Riyue Feng, Xiao Yu, Rui Zhu, Yenan Wu, Lei Li, Bin Yang, Yanchun Ma, Jiawei Wang, Wenjie Zhu, Dongjie Deng, Yanfeng Xi, Fang Wang, Hongyi Li, Shiping Guo, Xiaofei Zhuang, Xiaoyue Wang, Yuchen Jiao*, Yongping Cui*, Qimin Zhan*, Integrated Multi-omics Profiling Yields a Clinically-Relevant Molecular Classification for Esophageal Squamous Cell Carcinoma. Cancer Cell. 2023 Jan 9,41, 1-15. (IF=44.5)

6. Li Y#, Yang B, Ma Y, Peng X, Wang Z, Sheng B, Wei Z, Cui Y*, Liu Z*. Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy. 2021 Nov 12;6(1):381. (IF=52.7)

7. Yongping Cui#, Hongyan Chen#, Ruibin Xi#, Heyang Cui#, Yahui Zhao#, Enwei Xu#, Ting Yan, Xiaomei Lu, Furong Huang, Pengzhou Kong, Yang Li, Xiaolin Zhu, Jiawei Wang, Wenjie Zhu, Jie Wang, Yanchun Ma, Yong Zhou, Shiping Guo,Ling Zhang, Yiqian Liu, Bin Wang, Yanfeng Xi, Ruifang Sun, Xiao Yu, Yuanfang Zhai, Fang Wang, Jian Yang, Bin Yang, Caixia Cheng, Jing Liu, Bin Song, Hongyi Li, Yi Wang, Yingchun Zhang, Xiaolong Cheng, Qimin Zhan*, Yanhong Li*, Zhihua Liu*. Whole-genome Sequencing of 508 Patients Identifies Key Molecular Features Associated With Poor Prognosis in Esophageal Squamous Cell Carcinoma. Cell Research. 2020, 30(10):902-913. (IF=25.9)

8. Zhang Z#, Zhou L#, Xie N#, Nice E. C., Zhang T, Cui Y, & Huang C.Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy. 5(1).(2020). (IF=52.7)

主持科研项目：

1. 国家自然科学基金专项项目，82341024，150万元，结题，主持。

2. 国家重点研发计划“常见多发病防治研究”专项，2021YFC2501001，2600万，结题，子课题负责人。

3. 国家自然科学基金面上项目，81972613，55万元，结题，主持。

4. 国家重点研发计划“重大慢性非传染性疾病防控研究”重点专项，2016YFC1302100，960万元，结题，子课题负责人。

5. 国家自然科学基金重点项目，81330063，290万元，结题，主持。

6. 863计划生物和医药技术领域，SS2014AA020601，1000万元，结题，子课题负责人。

7. 广东省基础与应用基础研究重大项目，2019B030302012，4605万元，结题，子课题负责人。

8. 深圳市医学研究专项资金项目，C2303002，1000万元，在研，主持。

9. 深圳市“三名工程”高层次医学团队资助项目，SZSM202311014，1500万元，在研，骨干成员。